Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0151744 (myocardial ischemia)
 31,282 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Forty one patients with ischaemic heart disease (IHD) of the age 60 +/- 12.3 years were hospitalized and treated two weeks with Curantyl (Dipyridamol) which was applied per os in a dose of 75 mg 3 times, and after another two weeks 34 of them wass applied Isoptin (Verapamil) in a dose of 40 mg 3 times daily. The heat conductivity (J.m-1, sec-1.degree C.10(-2), HC) and skin temperature (degree C, ST) were examined at the isothermic level 2 cm above the inner ankle by the apparatus Fluvograph 2 of Hartmann and Braun A. G. (BRD). The HC after Isoptin application above the left and right ankle was in 34 patients increased significantly (p less than 0.001). In patients with IHD after Curantyl application the HC and ST was significantly decreased above the left and right ankle in 9 (21.9%) and in 12 (30.0%), respectively. Curantyl could deteriorate HC and so to worsen legs ulceration healing and to point ap ischemia in patients with associated chronic postphlebitic syndrome with ulcera crurium.
 ...
PMID:Heat conductivity and skin temperature at the treatment of ischemic heart disease with curantyl and isoptin. 207 72

Arterial hypertension, especially when co-exists with ischemic heart disease, makes an important clinical and social problem. Necessity to continue a treatment during the whole patients life produces many problems for a patient himself as well as for a physician. Thus, for many years, researches have been carried out to find a medicine that would allow to fully control blood pressure for all day, would have minimal side-effects and could be administered once a day. Beside convertase inhibitors such as Prestarium and Gopten, calcium channel blockers, especially retard verapamil forms like Isoptin SR-240 and SR-120 seem to be the most appropriate medicines, especially when hypertension is accompanied by ischemic heart disease and dysrrythmias. The study was performed in 150 hypertensive patients who were administered Isoptin SR-240 once a day and Isoptin SR-120 twice a day. That dose was sufficient to normalize benign and mild hypertension in most patients. Decreased frequency of dyshrrytmias and chest pain relief were also observed. Trials to increase daily dose up to 360 mg were accompanied by evident side effects such as dizziness and constipations. Much more profitable was to join lower Isoptin dose with convertase inhibitors and diuretics.
 ...
PMID:[Isoptin SR-240 and SR-120 in ambulatory treatment of arterial hypertension]. 875 74

The TEAM trial investigated the effectiveness and tolerance of a fixed combination of the ACE inhibitor and calcium channel blocker (2 mg trandolapril and 180 mg verapamil retard) (preparation Tarka) in an open multicentre prospective study of treatment of moderately severe hypertension (diastolic pressure at the end of the two-week wash-out period 100-115 mm Hg). The trial comprised 163 patients who were treated first for four weeks by a monotherapy with 2 mg trandolapril. After these four weeks patients who attained normal blood pressure proceeded with trandolapril treatment. Hypertensive patients who did not attain normal diastolic pressure levels were treated for another four weeks by a fixed combination of trandolapril and verapamil SR. After four weeks of treatment with trandolapril 62 patients of 163 (37%) had a diastolic blood pressure of less than 90 mm Hg. The fixed combination of trandolapril and verapamil SR reduced the diastolic blood pressure to less than 90 mm Hg in 71.6% of the patients resistant to treatment with 2 mg trandolapril and in another 15.6% of patients it reduced the diastolic blood pressure by 10 mm Hg or more. After two months of treatment 60 patients had a normal blood pressure due to trandolapril (37%) and another 73 patients (45%) treated by a combination of trandolapril and verapamil SR, i.e. a total of 133 patients (82%) who originally suffered from moderately severe hypertension, attained a normal diastolic blood pressure. The mean decrease of diastolic pressure after two months of treatment was 19.5 mm Hg in "non-respondents" to trandolapril monotherapy and 23.6 mm Hg in "respondents". The mean decrease of systolic pressure in "non-respondents" and "respondents" after trandolapril treatment was 19.5 mm Hg and 35.0 mm Hg resp. The fixed combination of trandolapril and verapamil was not only effective but was associated with a minimum of undesirable effects. The incidence of headaches declined significantly. The combination of the above preparations is useful also because both preparations have a cardio- and nephroprotective effect and do not affect the lipid and carbohydrate metabolism. Treatment with a fixed combination of trandolapril and verapamil SR is indicated in moderately severe hypertension not responding to monotherapy, in particular when associated with diabetes, hyperlipoproteinaemia, ischaemic heart disease or left ventricular hypertrophy.
 ...
PMID:[The TEAM study--a study of the effectiveness and tolerance of treatment of essential hypertension with a fixed combination of trandolapril and verapamil]. 982 54

The article focuses on the action of isoptin as a monotherapy and in the complex with mildronat in 67 patients with non-insulindependent diabetes mellitus (NIDM) and supraventricular arrhythmia. Isoptin has been shown to be a very effective drug in patients with atrial disorders of cardiac rhythm suffering from diabetes mellitus and ischemic heart disease, especially so in a complex therapy with mildronat. The results obtained permit recommending isoptin as an antiarrhythmic drug in NIDM patients.
 ...
PMID:[Isoptin in the therapy of supraventricular arrhythmia in patients with diabetes mellitus, non-insulin dependent, concurrent with ischemic heart disease]. 1188 47

The three currently available channel-blocking agents, nifedipine (Adalat), diltiazem (Cardiazem), and verapamil (Isoptin), are all useful in treating a number of cardiovascular disorders, especially ischemic heart disease. Although they have a common mechanism of action, their cardiovascular effects and pharmacological properties differ considerably. Each drug, consequently, has specific clinical indications; these drugs are not easily interchangeable. Understanding their properties and effects allows the physician to choose the particular drug most suited to the patient's needs.
 ...
PMID:Selecting a calcium channel-blocking agent. 2126 15